Abstract
Background: Parkinson’s disease (PD) is a neurodegenerative disease characterized by the loss of dopaminergic neurons within the substantia nigra pars compacta (SNpc). Despite many researches, there is still no cure for this disease. Levodopa is the first line treatment of PD, but the long term use of it leads to motor impairments and dyskinesias. The dopamine agonists are the preferred choice for the treatment of PD. They are neuroprotective in nature but have side effects.
Objective: Our aim was to review the work that has been carried out on dopamine agonists and the future possibilities to reduce their side effects.
Conclusion: In this review, we highlighted the metabolism of dopamine, different types of dopamine agonists with their properties and possible side effects.
Keywords: Neurodegenerative disease, dopamine, agonists, metabolism, neurotransmitters, central nervous system.
Graphical Abstract
Current Drug Targets
Title:Dopamine: Agonists and Neurodegenerative Disorders
Volume: 19 Issue: 14
Author(s): Saba Khanam and Yasir Hasan Siddique*
Affiliation:
- Drosophila Transgenic Laboratory, Section of Genetics, Department of Zoology, Faculty of Life Sciences, Aligarh Muslim University, Aligarh, Uttar Pradesh 202002,India
Keywords: Neurodegenerative disease, dopamine, agonists, metabolism, neurotransmitters, central nervous system.
Abstract: Background: Parkinson’s disease (PD) is a neurodegenerative disease characterized by the loss of dopaminergic neurons within the substantia nigra pars compacta (SNpc). Despite many researches, there is still no cure for this disease. Levodopa is the first line treatment of PD, but the long term use of it leads to motor impairments and dyskinesias. The dopamine agonists are the preferred choice for the treatment of PD. They are neuroprotective in nature but have side effects.
Objective: Our aim was to review the work that has been carried out on dopamine agonists and the future possibilities to reduce their side effects.
Conclusion: In this review, we highlighted the metabolism of dopamine, different types of dopamine agonists with their properties and possible side effects.
Export Options
About this article
Cite this article as:
Khanam Saba and Siddique Hasan Yasir*, Dopamine: Agonists and Neurodegenerative Disorders, Current Drug Targets 2018; 19 (14) . https://dx.doi.org/10.2174/1389450118666171117124340
DOI https://dx.doi.org/10.2174/1389450118666171117124340 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacogenetics of Parkinson’s Disease – Through Mechanisms of Drug Actions
Current Genomics Adenosine A2A Receptor Antagonists and Parkinsons Disease: State of the Art and Future Directions
Current Pharmaceutical Design Antipsychotic Drug Effects in Schizophrenia: A Review of Longitudinal fMRI Investigations and Neural Interpretations
Current Medicinal Chemistry Curcumin: A Potential Neuroprotective Agent in Parkinson's Disease
Current Pharmaceutical Design The Other Side of Opioid Receptor Signalling: Regulation by Protein-Protein Interaction
Current Drug Targets Issues in Rehabilitation of Cognitive Deficits in Schizophrenia: A Critical Review
Current Psychiatry Reviews Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges
Current Neuropharmacology Neuropeptidomics: Improvements in Mass Spectrometry Imaging Analysis and Recent Advancements
Current Protein & Peptide Science Tuning and Fine-Tuning of Synapses with Adenosine
Current Neuropharmacology Neurodegenerative Disease: A Perspective on Cell-Based Therapy in the New Era of Cell-Free Nano-Therapy
Current Pharmaceutical Design Tremor and Rigidity in Patients with Parkinson’s Disease: Emphasis on Epidemiology, Pathophysiology and Contributing Factors
CNS & Neurological Disorders - Drug Targets Nicotinic Receptors in Neurodegeneration
Current Neuropharmacology Anti-NMDA Receptor Encephalitis: Efficacy of Treatment for Male Patients and miRNA Biomarker
Current Medicinal Chemistry Cannabinoids: Between Neuroprotection and Neurotoxicity
Current Drug Targets - CNS & Neurological Disorders Advantages of Structure-Based Drug Design Approaches in Neurological Disorders
Current Neuropharmacology Potential Therapeutic Strategies of Phytochemicals in Neurodegenerative Disorders
Current Topics in Medicinal Chemistry Evolution of Antipsychotic Intervention in the Schizophrenic Psychosis
Current Drug Targets Bis(thiosemicarbazone) Metal Complexes as Therapeutics for Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System
Current Pharmaceutical Design Current Therapeutic Options for Alzheimers Disease
Current Genomics